Jiangsu Hengrui Medicine
600276.SS
#464
Rank
A$76.35 B
Marketcap
A$11.50
Share price
-1.44%
Change (1 day)
-5.03%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

EPS for Jiangsu Hengrui Medicine (600276.SS)

EPS in 2026 (TTM): A$0.22

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current EPS (TTM) is A$0.21. In 2025 the company made an earnings per share (EPS) of A$0.24 an increase over its 2024 EPS that were of A$0.20.

EPS history for Jiangsu Hengrui Medicine from 2000 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$0.22-7.89%
2025A$0.2424.14%
2024A$0.2042.43%
2023A$0.148.77%
2022A$0.13-20.62%
2021A$0.16-26.59%
2020A$0.2227.24%
2019A$0.1728.41%
2018A$0.1320.04%
2017A$0.1131.21%
2016A$0.0840711.46%
2015A$0.0754336.27%
2014A$0.0553519.77%
2013A$0.0462118.05%
2012A$0.0391523.9%
2011A$0.0316026.9%
2010A$0.0249012.37%
2009A$0.0221656.6%
2008A$0.014159.18%
2007A$0.01296114.48%
2006A$0.00604364.83%
2005A$0.00366635.55%
2004A$0.00270529.73%
2003A$0.00208519.86%
2002A$0.001739-2.71%
2001A$0.0017881.02%
2000A$0.001770